Ning Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ning Zhang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Wen Di
Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
9 shared publications Shibin Hong
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
7 shared publicationsChuan Wang
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
6 shared publicationsKa U. Lio
Department of Medicine, Temple University Hospital, Lewis Katz School of Medicine at Temple University, Philadelphia, USA
6 shared publicationsXin Kang
Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publicationsYiping Le
Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Research Square
Comparative Effectiveness of rhTPO and TPO Receptor Agonists in Severe, Refractory Immune Thrombocytopenia during Pregnancy: A Retrospective Analysis
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO), thrombopoietin receptor agonists (TPO-RAs), and their combination in pregnant patients with refractory severe immune thrombocytopenia (ITP) (platelet count < 30×10⁹/L,unresponsive to first-line corticosteroids/intravenous immunoglobulin [IVIG]). Methods This retrospective study enrolled 28 pregnant patients with severe ITP. Patients were assigned to three groups: rhTPO monotherapy (n = 16), TPO-RA monotherapy (eltrombopag, hetrombopag, or avatrombopag; n = 3), or combined rhTPO + TPO-RA therapy (n = 9). Efficacy (complete/partial/no response) was assessed 2 weeks post-treatment per standardized criteria. Safety (maternal adverse events, neonatal outcomes) and obstetric outcomes (gestational age at delivery, mode of delivery, postpartum hemorrhage) were analyzed. Results TPO-RA monotherapy achieved a 100% response rate (1 CR, 2 PR); rhTPO monotherapy had a 25% response rate (2 CR, 2 PR); combined therapy showed 0% response. No serious maternal adverse events occurred except 1 case of mild eltrombopag-related liver function impairment (resolved after switching to hetrombopag). Excluding 3 second-trimester medical inductions for treatment failure, 25 singleton live births were recorded, with only 1 neonate having thrombocytopenia (no severe neonatal complications). Conclusion TPO-RAs exhibit a favorable safety profile and promising efficacy in patients with refractory severe ITP, whereas rhTPO demonstrates a suboptimal response. Combined rhTPO + TPO-RAs therapy showed no responses, likely due to selection bias; thus, it is not routinely recommended, and sequential therapy (e.g., TPO-RA after rhTPO failure) may be a more rational approach. This study provides valuable insights for clinical decision-making in the absence of standardized second-line guidelines for gestational ITP, though large multicenter validation is needed.
- 10 August 2026
- Published by Springer Nature in Research Square
Open AccessComparative Effectiveness of rhTPO and TPO Receptor Agonists in Severe, Refractory Immune Thrombocytopenia during Pregnancy: A Retrospective Analysis
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO), thrombopoietin receptor agonists (TPO-RAs), and their combination in pregnant patients with refractory severe immune thrombocytopenia (ITP) (platelet count < 30×10⁹/L,unresponsive to first-line corticosteroids/intravenous immunoglobulin [IVIG]). Methods This retrospective study enrolled 28 pregnant patients with severe ITP. Patients were assigned to three groups: rhTPO monotherapy (n = 16), TPO-RA monotherapy (eltrombopag, hetrombopag, or avatrombopag; n = 3), or combined rhTPO + TPO-RA therapy (n = 9). Efficacy (complete/partial/no response) was assessed 2 weeks post-treatment per standardized criteria. Safety (maternal adverse events, neonatal outcomes) and obstetric outcomes (gestational age at delivery, mode of delivery, postpartum hemorrhage) were analyzed. Results TPO-RA monotherapy achieved a 100% response rate (1 CR, 2 PR); rhTPO monotherapy had a 25% response rate (2 CR, 2 PR); combined therapy showed 0% response. No serious maternal adverse events occurred except 1 case of mild eltrombopag-related liver function impairment (resolved after switching to hetrombopag). Excluding 3 second-trimester medical inductions for treatment failure, 25 singleton live births were recorded, with only 1 neonate having thrombocytopenia (no severe neonatal complications). Conclusion TPO-RAs exhibit a favorable safety profile and promising efficacy in patients with refractory severe ITP, whereas rhTPO demonstrates a suboptimal response. Combined rhTPO + TPO-RAs therapy showed no responses, likely due to selection bias; thus, it is not routinely recommended, and sequential therapy (e.g., TPO-RA after rhTPO failure) may be a more rational approach. This study provides valuable insights for clinical decision-making in the absence of standardized second-line guidelines for gestational ITP, though large multicenter validation is needed.
- Open Access
- 8 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Development and validation of a predictive model for septic shock in maternal sepsis: a retrospective cohort study in a single referral center
Maternal sepsis carries a high risk of progression to septic shock. However, existing risk stratification tools, such as qSOFA and the Sepsis in Obstetrics
- 8 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessDevelopment and validation of a predictive model for septic shock in maternal sepsis: a retrospective cohort study in a single referral center
Maternal sepsis carries a high risk of progression to septic shock. However, existing risk stratification tools, such as qSOFA and the Sepsis in Obstetrics
- Open Access
- 2 September 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 25 (1) , 1-11
The development and validation of postpartum hemorrhage prediction models for pregnancies with placenta previa totalis based on coagulation function indexes: a retrospective cohort study
The objective of this study is to establish and validate models that can accurately predict postpartum hemorrhage (PPH) in women with placenta previa totalis prior to undertaking cesarean delivery. A retrospective cohort study was conducted on 306 pregnancies with placenta previa totalis delivered between January 2011 and June 2022. The pregnancies were classified into two groups, PPH group and non-PPH group, based on bleeding volume and red blood cell transfusion. Clinical features and pre-operative coagulation function indexes were recorded. The entire cohort was randomly divided into a development cohort (n = 214) and a test cohort (n = 92). Least absolute shrinkage and selection operator (LASSO) was implemented to select significant predictors, followed by step-wise logistic regression analysis to build the prediction model. Additionally, machine learning-based models were compared with the proposed model. Among 306 participants, 115 (53.74%) and 50 (54.35%) cases of PPH were observed in the development and test cohorts, respectively. The LASSO-Logistic regression model incorporated preoperative serum fibrinogen level, history of prior cesarean delivery and history of antepartum bleeding as predictors. The model yielded an area under the receiver operating characteristic (ROC) curve of 0.721 (95% CI 0.652–0.790) in the development cohort and 0.706 (95% CI 0.600–0.813) in the test cohort. Additionally, the model demonstrated a specificity of 70.7% (95% CI 61.7–79.7%) and a positive predictive value of 72.1% (95% CI 63.5–80.7%) for distinguishing between PPH and non-PPH cases. The LASSO-Logistic regression model outperformed the machine learning based model in the test cohort, confirming its efficiency in predicting PPH in patients with placenta previa totalis. This study successfully developed and validated a LASSO-Logistic regression model incorporating coagulation indicators to predict PPH in patients with placenta previa totalis. Further large-scale prospective studies are warranted to externally validate the three-variate-based model and assess its practical application in real-time practice.
- 2 September 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 25 (1) , 1-11
Open AccessThe development and validation of postpartum hemorrhage prediction models for pregnancies with placenta previa totalis based on coagulation function indexes: a retrospective cohort study
The objective of this study is to establish and validate models that can accurately predict postpartum hemorrhage (PPH) in women with placenta previa totalis prior to undertaking cesarean delivery. A retrospective cohort study was conducted on 306 pregnancies with placenta previa totalis delivered between January 2011 and June 2022. The pregnancies were classified into two groups, PPH group and non-PPH group, based on bleeding volume and red blood cell transfusion. Clinical features and pre-operative coagulation function indexes were recorded. The entire cohort was randomly divided into a development cohort (n = 214) and a test cohort (n = 92). Least absolute shrinkage and selection operator (LASSO) was implemented to select significant predictors, followed by step-wise logistic regression analysis to build the prediction model. Additionally, machine learning-based models were compared with the proposed model. Among 306 participants, 115 (53.74%) and 50 (54.35%) cases of PPH were observed in the development and test cohorts, respectively. The LASSO-Logistic regression model incorporated preoperative serum fibrinogen level, history of prior cesarean delivery and history of antepartum bleeding as predictors. The model yielded an area under the receiver operating characteristic (ROC) curve of 0.721 (95% CI 0.652–0.790) in the development cohort and 0.706 (95% CI 0.600–0.813) in the test cohort. Additionally, the model demonstrated a specificity of 70.7% (95% CI 61.7–79.7%) and a positive predictive value of 72.1% (95% CI 63.5–80.7%) for distinguishing between PPH and non-PPH cases. The LASSO-Logistic regression model outperformed the machine learning based model in the test cohort, confirming its efficiency in predicting PPH in patients with placenta previa totalis. This study successfully developed and validated a LASSO-Logistic regression model incorporating coagulation indicators to predict PPH in patients with placenta previa totalis. Further large-scale prospective studies are warranted to externally validate the three-variate-based model and assess its practical application in real-time practice.
- Open Access
- 18 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-10
Hydroxychloroquine for preventing hypertensive pregnancy disorders in recurrent spontaneous abortion: a retrospective cohort study in a single referral center
We aimed to assess the effectiveness of hydroxychloroquine (HCQ) in preventing hypertensive pregnancy disorders (HPD) among women with recurrent spontaneous abortion (RSA). This retrospective cohort study included 462 pregnant women with RSA. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were used to balance baseline characteristics between HCQ and non-HCQ groups. The primary outcome comprised a composite of HPD, including preeclampsia, eclampsia, and gestational hypertension. Secondary outcomes included maternal complications and neonatal outcomes. HCQ was associated with a 62% decreased risk of HPD compared to no HCQ (weighted hazard ratio 0.38, 95% CI 0.16–0.94, P < 0.001). The cumulative incidence of HPD at 34 weeks was lower among HCQ users (5% vs 14%, P = 0.03). HCQ demonstrated greater efficacy in preventing HPD among women aged < 35 years, a body mass index (BMI) of ≥ 28, non-in vitro fertilization (IVF) pregnancies, and fewer than three prior miscarriages (P-interaction < 0.05). Notably, the risk of HPD was significantly lowered by 56 and 53% in combined HCQ and aspirin with/without low-molecular-weight heparin (LMWH) group compared with no HCQ counterpart, respectively. HCQ demonstrated promising efficacy in reducing HPD, particularly when used in conjunction with aspirin and/or LMWH therapy.
- 18 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-10
Open AccessHydroxychloroquine for preventing hypertensive pregnancy disorders in recurrent spontaneous abortion: a retrospective cohort study in a single referral center
We aimed to assess the effectiveness of hydroxychloroquine (HCQ) in preventing hypertensive pregnancy disorders (HPD) among women with recurrent spontaneous abortion (RSA). This retrospective cohort study included 462 pregnant women with RSA. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were used to balance baseline characteristics between HCQ and non-HCQ groups. The primary outcome comprised a composite of HPD, including preeclampsia, eclampsia, and gestational hypertension. Secondary outcomes included maternal complications and neonatal outcomes. HCQ was associated with a 62% decreased risk of HPD compared to no HCQ (weighted hazard ratio 0.38, 95% CI 0.16–0.94, P < 0.001). The cumulative incidence of HPD at 34 weeks was lower among HCQ users (5% vs 14%, P = 0.03). HCQ demonstrated greater efficacy in preventing HPD among women aged < 35 years, a body mass index (BMI) of ≥ 28, non-in vitro fertilization (IVF) pregnancies, and fewer than three prior miscarriages (P-interaction < 0.05). Notably, the risk of HPD was significantly lowered by 56 and 53% in combined HCQ and aspirin with/without low-molecular-weight heparin (LMWH) group compared with no HCQ counterpart, respectively. HCQ demonstrated promising efficacy in reducing HPD, particularly when used in conjunction with aspirin and/or LMWH therapy.
- Open Access
- 5 October 2024
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 90 (2) , 1-12
A Predictive Model for Treatment Effectiveness in Severe Primary Immune Thrombocytopenia during Pregnancy: A Retrospective Study in a Tertiary Critical Maternity Referral Center
Objectives: The study aimed to identify factors influencing the severity of primary immune thrombocytopenia (ITP) during pregnancy, develop a predictive model for treatment response, and report maternal and neonatal outcomes associated with severe ITP. Design: A retrospective analysis was conducted on 155 pregnancies with severe ITP between January 2018 and April 2023 at a tertiary critical maternity referral center in Shanghai, China. Participants/Materials: The study included 155 pregnancies diagnosed with severe ITP, divided into groups based on the lowest platelet count (<30 × 109/L vs. 30–50 × 109/L) and first-line treatment response (non-response vs. response). Setting: The study was conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, a tertiary critical maternity rescue referral center. Methods: Clinical characteristics and outcomes were compared between groups. A multivariable logistic regression model was used to identify factors associated with the severity of ITP. A prediction model for treatment response was established using LASSO-logistic regression and internally validated. Results: ITP severity was found to be correlated with low maximum amplitude of thromboelastography (OR 5.43, 95% CI: 1.48–16.00, p = 0.002), bleeding events (OR 4.91, 95% CI: 1.62–14.86, p = 0.005), and low reticulocytes (OR 2.40 × 10−7, 95% CI: 1.06 × 10−13 to 0.55, p = 0.04). Of the 118 patients who received first-line therapy, 52 (44%) responded. The dataset was randomly split into a training (N = 99) and test (N = 23) set with a ratio of 8:2. A predictive nomogram was created and internally validated showing good discrimination. The model yielded an area under receiver operating characteristic curve of 0.78 (0.69–0.87) and 0.85 (0.67–1.00) in the training and validation cohort, respectively. Earlier delivery and high rate of neonatal intensive care unit admission occurred with severe ITP and treatment failure. Limitations: The study was limited by a relatively small sample size and the retrospective observational design, which imposed limitations on the assessment of treatment efficacy. Conclusions: We identified clinical predictors of ITP severity and treatment resistance during pregnancy. A nomogram predicting first-line response was validated. These findings can facilitate clinical decision-making and counseling regarding this challenging pregnancy complication.
- 5 October 2024
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 90 (2) , 1-12
Open AccessA Predictive Model for Treatment Effectiveness in Severe Primary Immune Thrombocytopenia during Pregnancy: A Retrospective Study in a Tertiary Critical Maternity Referral Center
Objectives: The study aimed to identify factors influencing the severity of primary immune thrombocytopenia (ITP) during pregnancy, develop a predictive model for treatment response, and report maternal and neonatal outcomes associated with severe ITP. Design: A retrospective analysis was conducted on 155 pregnancies with severe ITP between January 2018 and April 2023 at a tertiary critical maternity referral center in Shanghai, China. Participants/Materials: The study included 155 pregnancies diagnosed with severe ITP, divided into groups based on the lowest platelet count (<30 × 109/L vs. 30–50 × 109/L) and first-line treatment response (non-response vs. response). Setting: The study was conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, a tertiary critical maternity rescue referral center. Methods: Clinical characteristics and outcomes were compared between groups. A multivariable logistic regression model was used to identify factors associated with the severity of ITP. A prediction model for treatment response was established using LASSO-logistic regression and internally validated. Results: ITP severity was found to be correlated with low maximum amplitude of thromboelastography (OR 5.43, 95% CI: 1.48–16.00, p = 0.002), bleeding events (OR 4.91, 95% CI: 1.62–14.86, p = 0.005), and low reticulocytes (OR 2.40 × 10−7, 95% CI: 1.06 × 10−13 to 0.55, p = 0.04). Of the 118 patients who received first-line therapy, 52 (44%) responded. The dataset was randomly split into a training (N = 99) and test (N = 23) set with a ratio of 8:2. A predictive nomogram was created and internally validated showing good discrimination. The model yielded an area under receiver operating characteristic curve of 0.78 (0.69–0.87) and 0.85 (0.67–1.00) in the training and validation cohort, respectively. Earlier delivery and high rate of neonatal intensive care unit admission occurred with severe ITP and treatment failure. Limitations: The study was limited by a relatively small sample size and the retrospective observational design, which imposed limitations on the assessment of treatment efficacy. Conclusions: We identified clinical predictors of ITP severity and treatment resistance during pregnancy. A nomogram predicting first-line response was validated. These findings can facilitate clinical decision-making and counseling regarding this challenging pregnancy complication.
- Open Access
- 14 June 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 6 (16) , 4082-4093
Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation
Resistance to platinum-based chemotherapy is the major cause of poor prognosis and cancer-associated mortality in ovarian cancer patients, so novel therapeutic strategies to restore platinum sensitivity are needed to improve patient outcomes. Sphingosine Kinase (SphK) 1 is involved in regulating multiple pro-survival pathways, key mediators in the sensitivity of tumor cells toward platinum. By encapsulating CBP and the SphK1 inhibitor PF543 in PLGA (poly lactic-co-glycolic acid) nanoparticles, a dual-drug delivery system (C/PNPs) was formed to simultaneously deliver CBP and PF543. The physicochemical characteristics, cell uptake rate and biodistribution behavior of C/PNPs were evaluated. Then the anti-tumor ability of C/PNPs in vitro and in vivo was further investigated. The C/PNPs could deliver CBP and PF543 simultaneously to a platinum-insensitive cell line (SKOV3) both in vitro and in vivo. Furthermore, benefiting from the enhanced permeability and retention (EPR) effect of PLGA NPs, C/PNPs exhibited an improved tumor region accumulation. As a result, a synergistic anti-tumor effect was found in the SKOV3 tumor-bearing mice, with tumor volume inhibiting rates of 84.64% and no side effects in major organs. The mechanistic studies confirmed that the inhibition of SphK1 by PF543 sensitized SKOV3 cells to CBP chemotherapy, partly by inhibiting the CBP-induced activation of pro-survival pathways, including ERK, AKT and STAT3 signaling. Our study reveals that C/PNPs can serve as an efficient dual-drug delivery system to restore platinum sensitivity in ovarian cancer models partly through inhibiting platinum-induced pro-survival pathway activation.
- 14 June 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 6 (16) , 4082-4093
Open AccessNanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation
Resistance to platinum-based chemotherapy is the major cause of poor prognosis and cancer-associated mortality in ovarian cancer patients, so novel therapeutic strategies to restore platinum sensitivity are needed to improve patient outcomes. Sphingosine Kinase (SphK) 1 is involved in regulating multiple pro-survival pathways, key mediators in the sensitivity of tumor cells toward platinum. By encapsulating CBP and the SphK1 inhibitor PF543 in PLGA (poly lactic-co-glycolic acid) nanoparticles, a dual-drug delivery system (C/PNPs) was formed to simultaneously deliver CBP and PF543. The physicochemical characteristics, cell uptake rate and biodistribution behavior of C/PNPs were evaluated. Then the anti-tumor ability of C/PNPs in vitro and in vivo was further investigated. The C/PNPs could deliver CBP and PF543 simultaneously to a platinum-insensitive cell line (SKOV3) both in vitro and in vivo. Furthermore, benefiting from the enhanced permeability and retention (EPR) effect of PLGA NPs, C/PNPs exhibited an improved tumor region accumulation. As a result, a synergistic anti-tumor effect was found in the SKOV3 tumor-bearing mice, with tumor volume inhibiting rates of 84.64% and no side effects in major organs. The mechanistic studies confirmed that the inhibition of SphK1 by PF543 sensitized SKOV3 cells to CBP chemotherapy, partly by inhibiting the CBP-induced activation of pro-survival pathways, including ERK, AKT and STAT3 signaling. Our study reveals that C/PNPs can serve as an efficient dual-drug delivery system to restore platinum sensitivity in ovarian cancer models partly through inhibiting platinum-induced pro-survival pathway activation.
- Open Access
- 2 April 2024
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-5
Successful management of VTE with essential thrombocythemia and cavernous transformation of the portal vein in early pregnancy: a case report
Due to the thrombohemorrhagic potential of essential thrombocythemia, pregnancy complicated by essential thrombocythemia should be recognized as a risk factor for obstetric complications. Here, we report the case of a patient with essential thrombocythemia with two significantly different pregnancy outcomes. Her first pregnancy (at 30 years of age) ended with an uneventful term delivery. However, the patient progressed to cavernous transformation of the portal vein in the period between her two pregnancies and subsequently experienced deep venous thrombosis during the first trimester of her second pregnancy (at 36 years of age). The patient’s platelet count during pregnancy was within the normal range, so she ignored previous instances of essential thrombocytosis (at 26 years of age). The patient’s main symptom was unrelieved pain in her leg. After that, she was successfully treated with anticoagulant throughout her entire pregnancy, resulting in a term vaginal delivery. This case highlights the importance of assessing pregnant patients with essential thrombocythemia according to their risk stratification. Specifically, risk assessments for potential pregnancy complications should take into account advanced maternal age and a previous history of thrombosis. Patients with essential thrombocythemia should be encouraged to participate in preconception counseling for risk assessment and to initiate prophylactic anticoagulation as soon as possible.
- 2 April 2024
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-5
Open AccessSuccessful management of VTE with essential thrombocythemia and cavernous transformation of the portal vein in early pregnancy: a case report
Due to the thrombohemorrhagic potential of essential thrombocythemia, pregnancy complicated by essential thrombocythemia should be recognized as a risk factor for obstetric complications. Here, we report the case of a patient with essential thrombocythemia with two significantly different pregnancy outcomes. Her first pregnancy (at 30 years of age) ended with an uneventful term delivery. However, the patient progressed to cavernous transformation of the portal vein in the period between her two pregnancies and subsequently experienced deep venous thrombosis during the first trimester of her second pregnancy (at 36 years of age). The patient’s platelet count during pregnancy was within the normal range, so she ignored previous instances of essential thrombocytosis (at 26 years of age). The patient’s main symptom was unrelieved pain in her leg. After that, she was successfully treated with anticoagulant throughout her entire pregnancy, resulting in a term vaginal delivery. This case highlights the importance of assessing pregnant patients with essential thrombocythemia according to their risk stratification. Specifically, risk assessments for potential pregnancy complications should take into account advanced maternal age and a previous history of thrombosis. Patients with essential thrombocythemia should be encouraged to participate in preconception counseling for risk assessment and to initiate prophylactic anticoagulation as soon as possible.
- Open Access
- 26 June 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-6
Acute intestinal pseudo-obstruction secondary to Sjogren’s syndrome in pregnancy: a case report and literature review
Background: Intestinal pseudo-obstruction (IPO) is a rare disease, and its clinical manifestations can resemble mechanical intestinal obstruction leading to unnecessary and potentially harmful surgery. Certain autoimmune diseases have been associated with IPO, however, cases secondary to Sjögren’s syndrome (SjS) are especially rare. Case presentation: We described the first case of SjS-associated acute IPO in pregnancy, which was successfully treated with combined immunosuppressive therapy and resulted in an uneventful caesarean delivery. Conclusions: Women with SjS is likely to experience more complications during pregnancy, and IPO rather than the classic symptoms could be the first sign of SjS flares. IPO should be suspected in patients with unrelenting symptoms of small bowel obstruction, and a multidisciplinary approach can provide optimal management of such high-risk pregnancies.
- 26 June 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-6
Open AccessAcute intestinal pseudo-obstruction secondary to Sjogren’s syndrome in pregnancy: a case report and literature review
Background: Intestinal pseudo-obstruction (IPO) is a rare disease, and its clinical manifestations can resemble mechanical intestinal obstruction leading to unnecessary and potentially harmful surgery. Certain autoimmune diseases have been associated with IPO, however, cases secondary to Sjögren’s syndrome (SjS) are especially rare. Case presentation: We described the first case of SjS-associated acute IPO in pregnancy, which was successfully treated with combined immunosuppressive therapy and resulted in an uneventful caesarean delivery. Conclusions: Women with SjS is likely to experience more complications during pregnancy, and IPO rather than the classic symptoms could be the first sign of SjS flares. IPO should be suspected in patients with unrelenting symptoms of small bowel obstruction, and a multidisciplinary approach can provide optimal management of such high-risk pregnancies.
- 18 January 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (1) , 89-93
Multidisciplinary approach for the management of term pregnancy complicated by Eisenmenger syndrome
概要 妊娠合并心脏病的发病率为0.5%~3.0%,是导致孕产妇死亡的非产科病因首位。而重度肺动脉高压的处理最为棘手,合并艾森曼格综合征的孕产妇死亡率高达30%~50%,剖宫产患者甚至达65%~75%。妊娠合并重度肺动脉高压属于妊娠禁忌,一旦诊断需尽快终止妊娠,能达足月妊娠者临床非常罕见。本文报道一例足月妊娠合并重度肺动脉高压和艾森曼格综合征患者的成功诊治,旨在提高产科医师对该合并症的重视和多学科管理,并提高对该疾病围手术期的精细诊疗水平。
- 18 January 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (1) , 89-93
Multidisciplinary approach for the management of term pregnancy complicated by Eisenmenger syndrome
概要 妊娠合并心脏病的发病率为0.5%~3.0%,是导致孕产妇死亡的非产科病因首位。而重度肺动脉高压的处理最为棘手,合并艾森曼格综合征的孕产妇死亡率高达30%~50%,剖宫产患者甚至达65%~75%。妊娠合并重度肺动脉高压属于妊娠禁忌,一旦诊断需尽快终止妊娠,能达足月妊娠者临床非常罕见。本文报道一例足月妊娠合并重度肺动脉高压和艾森曼格综合征患者的成功诊治,旨在提高产科医师对该合并症的重视和多学科管理,并提高对该疾病围手术期的精细诊疗水平。
- Open Access
- 22 September 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 912419
Cerebral venous thrombosis as a rare cause of nausea and vomiting in early pregnancy: Case series in a single referral center and literature review
Objectives: Cerebral venous thrombosis (CVT) in early pregnancy is extremely rare and evidence limited to only a few published reports. This study aims to present our experience and summarize the available literature to further elucidate the clinical manifestations, treatment, and outcomes of CVT in early pregnancy.Methods: A retrospective case series of seven patients diagnosed with CVT in early pregnancy (n = 5, 71.4%), limb weakness (n = 4, 57.1%), seizures (n = 2, 28.6%), altered mental status (n = 3, 42.9%), and blurred vision (n = 2, 28.6%). All the patients were diagnosed with CVT by neuroimaging, which revealed various extents of sinus involvement, with the transverse sinus being the most common site (n = 7, 100%) followed by the sigmoid sinus (n = 5, 71.4%). All the patients received subcutaneous low-molecular-weight heparin once the diagnosis was confirmed. Two patients with rapid deterioration underwent venous thrombectomy, and one patient subsequently underwent decompressive craniotomy but died despite the above interventions. All the other patients proceeded with induced abortion after stabilization and were discharged on oral anticoagulation for 1 year. On the 12-month follow-up, the MRI/magnetic resonance venography (MRV) revealed recanalization of sinuses and resolution of thrombi.Conclusions: Cerebral venous thrombosis (CVT) in early pregnancy represents a diagnostic challenge given its rarity and nonspecific overlapping clinical features with nausea and vomiting of pregnancy/hyperemesis gravidarum (NVP/HG), which could lead to delay in diagnosis and result in rapid deterioration. Persistent or aggravating headaches combined with other focalizing neurological symptoms in NVP/HG patients could be an initial sign of CVT. Urgent MRI/MRV remains the cornerstone for diagnosis, and immediate anticoagulation is the key for disease prognosis. Glasgow coma scale (GCS) evaluation on admission is probably correlated with the prognosis. Early pregnancy combined with CVT is not a contraindication of continued pregnancy.
- 22 September 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 912419
Open AccessCerebral venous thrombosis as a rare cause of nausea and vomiting in early pregnancy: Case series in a single referral center and literature review
Objectives: Cerebral venous thrombosis (CVT) in early pregnancy is extremely rare and evidence limited to only a few published reports. This study aims to present our experience and summarize the available literature to further elucidate the clinical manifestations, treatment, and outcomes of CVT in early pregnancy.Methods: A retrospective case series of seven patients diagnosed with CVT in early pregnancy (n = 5, 71.4%), limb weakness (n = 4, 57.1%), seizures (n = 2, 28.6%), altered mental status (n = 3, 42.9%), and blurred vision (n = 2, 28.6%). All the patients were diagnosed with CVT by neuroimaging, which revealed various extents of sinus involvement, with the transverse sinus being the most common site (n = 7, 100%) followed by the sigmoid sinus (n = 5, 71.4%). All the patients received subcutaneous low-molecular-weight heparin once the diagnosis was confirmed. Two patients with rapid deterioration underwent venous thrombectomy, and one patient subsequently underwent decompressive craniotomy but died despite the above interventions. All the other patients proceeded with induced abortion after stabilization and were discharged on oral anticoagulation for 1 year. On the 12-month follow-up, the MRI/magnetic resonance venography (MRV) revealed recanalization of sinuses and resolution of thrombi.Conclusions: Cerebral venous thrombosis (CVT) in early pregnancy represents a diagnostic challenge given its rarity and nonspecific overlapping clinical features with nausea and vomiting of pregnancy/hyperemesis gravidarum (NVP/HG), which could lead to delay in diagnosis and result in rapid deterioration. Persistent or aggravating headaches combined with other focalizing neurological symptoms in NVP/HG patients could be an initial sign of CVT. Urgent MRI/MRV remains the cornerstone for diagnosis, and immediate anticoagulation is the key for disease prognosis. Glasgow coma scale (GCS) evaluation on admission is probably correlated with the prognosis. Early pregnancy combined with CVT is not a contraindication of continued pregnancy.